Sin­ga­pore’s Aslan Phar­ma lines up an $86M IPO to fund piv­otal can­cer drug stud­ies

With its lead on­col­o­gy drug in a piv­otal study for bil­iary tract can­cer and a slate of key cat­a­lysts com­ing up in oth­er tri­als, Sin­ga­pore-based Aslan Phar­ma­ceu­ti­cals has filed for an IPO on Nas­daq, with plans to raise around $86 mil­lion. Helmed by Carl Firth — the for­mer BD chief for As­traZeneca in Asia who owns 4.7% of the stock — Aslan is a small biotech with a glob­al strat­e­gy to roll out its can­cer drugs in Chi­na, the US and Eu­rope. The lead is var­l­i­tinib, a pan-HER drug that is al­so in the clin­ic for gas­tric, breast and col­orec­tal can­cers. The com­pa­ny plans to trade un­der the $ASLN sym­bol, tak­ing ad­van­tage of the cur­rent hot mar­ket for biotechs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER